Home Blog of Signal Transduction Protein Tyrosine Kinase PDGFR

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

PDGFR

PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, relieves airway hyperresponsiveness, mucus hypersecretion and inflammation in a murine asthma model

218 views | Jan 14 2024

PP121, a dual tyrosine and phosphoinositide kinase inhibitor, demonstrates promising anti-contractile and anti-inflammatory effects in asthma treatment, suggesting its potential as a novel therapeutic compound for managing the condition. [Read the Full Post]

Sertad1 Induces Neurological Injury after Ischemic Stroke via the CDK4/p-Rb Pathway

234 views | Jan 06 2024

Sertad1, upregulated in ischemic conditions, exacerbates neurological injury by activating the CDK4/p-Rb pathway, promoting cell cycle dysregulation and apoptotic cell death. [Read the Full Post]

Single-cell RNA sequencing identifies an Il1rn+/Trem1+ macrophage subpopulation as a cellular target for mitigating the progression of thoracic aortic aneurysm and dissection

109 views | Dec 08 2023

The study on thoracic aortic aneurysm and dissection (TAAD) utilizing single-cell RNA sequencing in a mouse model identified the Il1rn+/Trem1+ pro-inflammatory macrophage subpopulation as the predominant source of detrimental molecules, highlighting the potential of targeted therapy, specifically via Trem1 blockade, as a promising medical treatment for TAAD. [Read the Full Post]

Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials

61 views | Dec 04 2023

The systematic review and meta-analysis demonstrate that transarterial chemoembolization (TACE) combined with multikinase inhibitors (MKIs) significantly prolongs time to progression and improves objective response rates, but does not significantly impact overall or progression-free survival in patients with unresectable hepatocellular carcinoma, highlighting the importance of managing MKI-related toxicities in future clinical applications. [Read the Full Post]

Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity

78 views | Nov 20 2023

Using advanced molecular dynamics simulations, researchers identified masitinib's stable hydrogen bond interactions with the Mpro enzyme, pinpointing the crucial role of His163, leading to the design of effective derivatives M3 and M4 with increased inhibitory efficiency against SARS-CoV-2. [Read the Full Post]

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study

82 views | Oct 01 2023

The study demonstrated that oral vorolanib improved visual outcomes in participants with neovascular age-related macular degeneration (nAMD) while maintaining a manageable safety profile. [Read the Full Post]

Diazoxide improves muscle function in association with improved dyslipidemia and decreased muscle oxidative stress in streptozotocin-induced diabetic rats

85 views | Sep 27 2023

Diazoxide administration in diabetic rats improves muscle strength development, reduces fatigue, lowers cholesterol and triglyceride levels, and improves oxidative stress parameters, suggesting its potential as a therapeutic intervention for diabetes-related complications. [Read the Full Post]

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors

129 views | Aug 26 2023

AZD3229 is a potent and selective small-molecule inhibitor with the potential to be a best-in-class treatment for a broad range of primary and imatinib-resistant secondary mutations in gastrointestinal stromal tumor (GIST). [Read the Full Post]

Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval

93 views | Aug 24 2023

Ripretinib, a switch-control tyrosine kinase inhibitor, has shown promise in targeting both primary and secondary KIT and PDGFRα resistance mutations, making it a valuable therapeutic option in the management of advanced gastrointestinal stromal tumors (GISTs) that have developed resistance to imatinib and other treatments. [Read the Full Post]

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

130 views | Aug 24 2023

The Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) recommend a multidisciplinary approach and centralized management in reference centers for the diagnosis and treatment of gastrointestinal stromal tumor (GIST) patients. [Read the Full Post]